Belenfant Xavier, Tabbi Anani Wided, Roland Mélanie, Mavel Marie-Christine, Laederich Joelle
Hôpital André-Grégoire, service de néphrologie dialyse, 93100 Montreuil-sous-Bois, France.
Presse Med. 2012 Mar;41(3 Pt 1):304-10. doi: 10.1016/j.lpm.2011.12.003. Epub 2012 Jan 27.
The objectives are to slow the progression of chronic kidney disease (CKD), to take all the cardiovascular risk factors into account, to screen for and treat specific complications and to prepare, if necessary, for renal replacement treatment (transplantation or dialysis). The principal treatment targets are: blood pressure less than 130/80 mmHg and proteinuria less than 0.5 g/day (ratio of proteinuria/creatinuria <50mg/mmol). The first-line treatment to reach these goals is angiotensin conversion enzyme inhibitors (ACE inhibitors), combined with diet and other life style changes. The periodicity of clinical and laboratory assessments depends on the CKD stage, the speed of disease progression and the need to reassess the impact of therapeutic interventions. Comprehensive multidisciplinary management can slow or even stop the progression of CKD and reduce its cardiovascular complications, which are the leading cause of death in these patients.
目标是减缓慢性肾脏病(CKD)的进展,考虑所有心血管危险因素,筛查并治疗特定并发症,必要时为肾脏替代治疗(移植或透析)做准备。主要治疗目标是:血压低于130/80 mmHg,蛋白尿低于0.5 g/天(蛋白尿/肌酐尿比值<50mg/mmol)。达到这些目标的一线治疗是血管紧张素转换酶抑制剂(ACE抑制剂),同时结合饮食和其他生活方式的改变。临床和实验室评估的周期取决于CKD分期、疾病进展速度以及重新评估治疗干预效果的必要性。全面的多学科管理可以减缓甚至阻止CKD的进展,并减少其心血管并发症,而心血管并发症是这些患者的主要死因。